Fixed drug eruption (FDE) is a type of cutaneous drug reaction that typically appears as round erythematous and edematous plaques (sometimes with a central blister) at the same site on the skin or mucous membranes and begins 1-2 weeks after the initial exposure to the drug. With subsequent exposures, lesions reactivate within 24 hours and then fade away over several days, often leaving residual, postinflammatory, grayish-brown pigmentation [1] .
Antibacterial agents (eg, trimethoprim-sulfamethoxazole, tetracyclines, penicillins) and nonsteroidal anti-inflammatory drugs (NSAIDs) are considered to be the main causes of FDE [1] .
Etoricoxib is a selective COX-2 inhibitor. It is usually safe and well tolerated in patients with hypersensitivity to NSAIDs [2] . Nevertheless, some cases of FDE with this drug have been reported [1, 3, 4] , as has a case of symmetrical drugrelated intertriginous and flexural exanthema (SDRIFE) [5] and, recently, a case of anaphylaxis to etoricoxib [6] .
The lymphocyte transformation test (LTT) is a useful diagnostic technique in nonimmediate drug reactions [4] , although its usefulness in the diagnosis of FDE is open to debate [7, 8] .
In July 2017, a 46-year-old woman was seen in the allergy unit for an adverse reaction to etoricoxib. She had been diagnosed with cold urticaria in 2007, although this was well controlled with antihistamines. She had experienced 3 episodes of bilateral palpebral angioedema 90 minutes after taking ibuprofen 600 mg in 2008. The diagnostic work-up indicated possible hypersensitivity to NSAIDs. The drug-controlled exposure test performed at that time revealed tolerance to meloxicam 15 mg and etoricoxib 60 mg. In 2016, the patient had received etoricoxib (1 tablet, 5 days) for trochanteritis. She tolerated the therapy well.
In March 2017, the patient noticed pruritic and maculopapular lesions on her face and a single burning macular lesion (2 cm) twice at the same site on the left side of the abdomen after taking 1 etoricoxib tablet. She was treated with oral antihistamines and topical corticosteroids. The facial lesions disappeared 3 days later. Residual hyperpigmentation was observed on the abdominal lesion. The LTT was performed 4 months after remission according to Pichler and Tilch [7] with etoricoxib, celecoxib, and sulfamethoxazole and was positive with all 3 drugs ( Figure) . Briefly, peripheral blood mononuclear cells (2×10 5 cells in 200 μL) were stimulated with increasing concentrations of the suspect drugs in triplicate for 6 days in RPMI culture medium supplemented with 5% autologous serum, and 0.5 μCi of 3H-thymidine was added to the cultures for the last 18 hours. The cell cultures were harvested using glass fiber filters, and radioactivity was measured using a scintillation beta counter. Proliferation was evaluated by incorporating 3H-thymidine to DNA. A stimulation index (SI) was calculated as the ratio of 3H incorporated by drug-stimulated cultures to baseline incorporation of 3H by unstimulated cells. The LTT result was considered positive if the SI was higher than 2 [7] . The SI was 5.9 and 6.2 for etoricoxib at 50 μg/mL and 100 μg/mL and 2.2 and 4.2 for celecoxib at 10 μg/mL and 100 μg/mL. The SI value for sulfamethoxazole was 4.1 and 3.3 at 10 and 200 μg/mL, respectively.
The number of new drugs in the pharmaceutical industry is growing quickly, as is the number of adverse cutaneous drug reactions to these drugs. Approximately 100 drugs have been found to cause FDE, although only 8 cases of etoricoxib-related FDE have been reported [1, 3, 4] .
Etiologic confirmation of FDE is sometimes problematic, particularly in polymedicated patients [1] . Few authors have assessed the diagnostic value of LTT for FDE [7, 8] . Pichler and Tilch [7] suggested that LTT in patients with FDE is consistently negative. Nevertheless, Kim et al [8] used LTT to confirm that allopurinol was the culprit drug in a case of allopurinol-induced FDE. We used LTT to confirm etoricoxib as the culprit drug in a patient with FDE and to show possible cross-reactivity with sulfamethoxazole and celecoxib.
Sulfonamides are among the main causes of FDE. Opinions on cross-reactivity between sulfonamide antibiotics and nonantibiotics vary considerably [9] . Muntingh [9] found that patients allergic to sulfonamide antibiotics were more likely to react to sulfonamide nonantibiotics than nonallergic patients. In a recent case report published by our group, the LTT did not reveal cross-reactivity between sulfamethoxazole and sulfadiazine [10] . The new COX-2 inhibitors, such as celecoxib and etoricoxib, contain a sulfone-group. We recorded a positive LTT result with etoricoxib, celecoxib, and sulfamethoxazole. In the case of etoricoxib-induced SDRIFE, the results of patch testing with etoricoxib and celecoxib were positive [5] , thus enabling us to hypothesize about possible cross-reactivity between etoricoxib and sulfamethoxazole and also with other drugs containing a sulfone group. However, our in vitro study is limited by the absence of a controlled exposure test and patch tests, with the result that a positive LTT result does not necessarily imply a clinical response.
We think epitopes in sulfonamides may differ between patients and that the antibodies to these drugs could have different reactivities. Therefore, it is necessary to assess crossreactivity on an individual basis.
It is important to emphasize that the patient in the present report took etoricoxib safely for some time before becoming sensitized to the drug. This interesting finding requires further investigation. Etoricoxib may be not as safe as previously thought.
Our results suggest that LTT could be useful for identifying the culprit drug in FDE, a type IV drug hypersensitivity reaction, although this hypothesis should be confirmed in large samples. Lenalidomide is an immunomodulatory and antiangiogenic agent approved for the treatment of oncological and inflammatory diseases, such as multiple myeloma, myelodysplastic syndrome (MDS), and mantle cell lymphoma. It is administered alone or with dexamethasone in relapsed and refractory multiple myeloma or as maintenance therapy following autologous stem cell transplantation [1] .
Lenalidomide has been associated with cutaneous eruptions [2] . Lowering the dose to prevent cutaneous reactions is ineffective [3, 4] . Skin reactions have been described in approximately 21% of patients and are the most frequent adverse event with this drug [5] .
Truly allergic reactions are difficult to distinguish from toxic adverse effects in patients receiving lenalidomide. Immediate and delayed hypersensitivity reactions are rare, with only a few cases reported, most of which did not involve a complete allergological work-up [6] . Hypersensitivity reactions include urticaria, exanthema, drug reaction with eosinophilia and systemic symptoms syndrome, Stevens-Johnson syndrome, and toxic epidermal necrolysis [2, 3, 7] .
We report a case involving both skin toxicity and a true delayed hypersensitivity reaction to lenalidomide.
The patient was a 78-year-old man with a history of prostate cancer in 2012 in complete remission and current del (5q) MDS type RAEB 1. He started treatment with 10 mg of lenalidomide for 21 days every 28 days. Following the second cycle, 3 days after the dose, he developed erythematous maculopapular exanthema on the thorax, back, and limbs, with no mucosal or systemic involvement. Oral corticosteroids were administered, and the reaction resolved within 15 days. Lenalidomide was discontinued, and he was referred to our allergy department. After signing an informed consent document, the patient underwent patch tests with lenalidomide at 10% in dimethyl sulfoxide (DMSO), and readings at day 2 and day 4 were negative. We performed patch tests with lenalidomide in DMSO because it is a useful vehicle that Manuscript received October 31, 2018; accepted for publication January 30, 2019.
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